Understanding immune responses to improve vaccine effectiveness against Staphylococcus aureus infections
Official title: Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
Funded at Abvacc, INC. · NIH-10832585 · Data updated 2026-11-12
This study is looking at how our immune system fights off a bacteria called Staphylococcus aureus, which can cause serious infections, to help improve vaccines and treatments for people who might get these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | March 12, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $619,311 |
| NIH project number | 5R01AI146177-05 |
| Project ID | NIH-10832585 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for Staphylococcus aureus infections, such as those undergoing cardiothoracic surgery or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for Staphylococcus aureus infections or those who have already been vaccinated against it may not benefit from this research.
What this research studies
This research investigates how the immune system responds to Staphylococcus aureus, a bacteria that can cause severe bloodstream infections. It aims to identify the immune mechanisms that can either protect against or worsen these infections, particularly in the context of vaccine development. The study will analyze immune responses in patients to determine why previous vaccine attempts have failed and how to improve future vaccine efficacy. By focusing on the immune responses that lead to better outcomes, the research seeks to develop effective host-directed therapies.
Why it matters
Potential benefit: If successful, this research could lead to the development of a safe and effective vaccine against Staphylococcus aureus bloodstream infections, significantly reducing morbidity and mortality.
How similar studies have gone: While there have been challenges in developing effective vaccines against Staphylococcus aureus, understanding immune responses has shown promise in other infectious disease research, indicating potential for success in this area.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
Related research
Other NIH-funded projects on the same topics.
-
Multimodal antibody therapy to treat Staphylococcus aureus bloodstream infections
A hospital-focused immunotherapy approach uses a mix of antibodies to help fight blood infections from Staphylococcus aureus by blocking immune evasion and bacterial growth.
-
Monoclonal antibody cocktail to treat Marburg virus disease
A new antibody-based treatment approach is being developed to help people infected with Marburg virus, using a combination of two targeted antibodies.
-
Vaccine to prevent repeat Staph (Staphylococcus aureus) infections
A multivalent toxoid vaccine called IBT-V02 aims to protect adults who get recurrent Staph aureus infections by neutralizing the bacteria's toxins and strengthening immune responses.
-
Treatment for Marburg Virus Disease using Monoclonal Antibodies
This study is testing a new treatment made from special antibodies to help people with Marburg Virus Disease, aiming to make it safer and more effective for those who are affected by this serious illness.
-
Developing a treatment to protect healthcare workers from Marburg virus outbreaks
This study is working on a new treatment to help protect healthcare workers and first responders from the Marburg virus, which can be very dangerous, by using special antibodies that can keep them safe during outbreaks.
-
Creating a vaccine to protect against Marburg virus disease
This study is working on a new vaccine to help protect people from Marburg virus disease, which currently has no approved vaccines or treatments, by creating a special ingredient that boosts the immune response while keeping it safe and effective.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.